ContraFect (NASDAQ:CFRX) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of ContraFect (NASDAQ:CFRXGet Rating) in a research report issued on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.

ContraFect Price Performance

Shares of NASDAQ CFRX opened at $0.14 on Friday. The firm has a market cap of $5.66 million, a price-to-earnings ratio of -0.12 and a beta of 0.35. ContraFect has a one year low of $0.13 and a one year high of $4.54. The stock’s fifty day moving average price is $0.18 and its two-hundred day moving average price is $1.47.

ContraFect (NASDAQ:CFRXGet Rating) last issued its quarterly earnings data on Monday, August 15th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). On average, equities analysts anticipate that ContraFect will post -1.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ContraFect

Institutional investors have recently modified their holdings of the company. Virtu Financial LLC purchased a new position in shares of ContraFect during the 3rd quarter worth approximately $31,000. Envestnet Asset Management Inc. bought a new position in ContraFect in the 1st quarter worth $41,000. Avantax Advisory Services Inc. increased its stake in ContraFect by 25.3% in the 3rd quarter. Avantax Advisory Services Inc. now owns 325,908 shares of the biotechnology company’s stock worth $55,000 after buying an additional 65,854 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of ContraFect by 62.9% during the first quarter. Dimensional Fund Advisors LP now owns 112,782 shares of the biotechnology company’s stock valued at $412,000 after purchasing an additional 43,564 shares in the last quarter. Finally, State Street Corp grew its position in ContraFect by 33.5% in the first quarter. State Street Corp now owns 129,817 shares of the biotechnology company’s stock worth $474,000 after acquiring an additional 32,563 shares in the last quarter. 63.80% of the stock is currently owned by institutional investors.

About ContraFect

(Get Rating)

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia.

Recommended Stories

Analyst Recommendations for ContraFect (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.